Former executive at Procter & Gamble, Nestlé, and Carrefour, Pierre-Alexandre leads ODDIFACT’s strategy. He has founded four startups and is a graduate of ENA, Sciences Po, and Harvard Kennedy School.

A serial tech entrepreneur with three software startups, Mehdi-Alexandre leads ODDIFACT’s AI roadmap and product innovation. EM Lyon graduate specialized in innovation and strategy.

Jules supports ODDIFACT’s program strategy through pharmaceutical analysis, prioritizing opportunities, aligning programs with partner expectations, and leading the use of AI tools across pharmaceutical processes.

Miren supports the development and structuring of regulatory documentation, contributing to orphan designation dossiers and related program materials.

With a PhD in Physical Chemistry and 18+ years of research experience, including data science in healthcare, Zahra contributes to AI-driven models and intelligent medical agents for rare disease analysis.

PhD in Artificial Intelligence from Inria, Hugo contributes to core AI development, computational modeling, and platform scalability.

With senior biopharmaceutical leadership roles at Roche, Pfizer, and Pierre Fabre, Yannick provides scientific guidance and medical insight across ODDIFACT’s rare disease strategy.